Development and validation of a microRNA-based diagnostic assay for classification of renal cell carcinomas

Molecular Oncology

Volumn 7, Issue 3, 2013, Pages 732-738

  Spector, Yael ^a   Fridman, Eddie ^b,c   Rosenwald, Shai ^a   Zilber, Sofia ^d   Huang, Yajue ^e   Barshack, Iris ^b,c   Zion, Orit ^a   Mitchell, Heather ^f   Sanden, Mats ^f   Meiri, Eti ^a  

^a ROSETTA GENOMICS LTD   (Israel)

^b SHEBA MEDICAL CENTER   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

^d RABIN MEDICAL CENTER   (Israel)

^e TEMPLE UNIVERSITY HOSPITAL   (United States)

^f Rosetta Genomics   (United States)

Author keywords

Kidney cancer; MicroRNA; Molecular diagnostics; Renal cell carcinoma

Indexed keywords

MICRORNA; MICRORNA 125B; MICRORNA 126; MICRORNA 200A;

ARTICLE; CANCER CLASSIFICATION; CANCER INCIDENCE; CELL ASSAY; CLASSIFICATION ALGORITHM; CLEAR CELL CARCINOMA; DIAGNOSTIC ACCURACY; GENE EXPRESSION; HISTOLOGY; HUMAN; HYBRIDIZATION; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; ONCOCYTOMA; PAPILLARY CARCINOMA; PREDICTIVE VALUE; PREVALENCE; PRIORITY JOURNAL; REPRODUCIBILITY; RNA EXTRACTION; SENSITIVITY AND SPECIFICITY;

EID: 84878129741     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2013.03.002     Document Type: Article

References (42)

1. Abel E.J., et al. Percutaneous biopsy of primary tumor in metastatic renal cell carcinoma to predict high risk pathological features: comparison with nephrectomy assessment. J.Urol. 2010, 184(5):1877-1881.
2. Allory Y., et al. Profiling and classification tree applied to renal epithelial tumours. Histopathology 2008, 52(2):158-166.
3. Barshack I., et al. MicroRNA expression differentiates between primary lung tumors and metastases to the lung. Pathol. Res. Pract. 2010, 206(8):578-584.
4. Bentwich I. A postulated role for microRNA in cellular differentiation. Faseb J. 2005, 19(8):875-879.
5. Blumenfeld A.J., et al. Percutaneous biopsy of renal cell carcinoma underestimates nuclear grade. Urology 2010, 76(3):610-613.
6. Bodmer D., et al. Understanding familial and non-familial renal cell cancer. Hum. Mol. Genet. 2002, 11(20):2489-2498.
7. Calin G.A., Croce C.M. MicroRNA signatures in human cancers. Nat. Rev. Cancer 2006, 6(11):857-866.
8. Camps C., et al. hsa-miR-210 Is induced by hypoxia and is an independent prognostic factor in breast cancer. Clin. Cancer Res. 2008, 14(5):1340-1348.
9. Cheng L., et al. Molecular and cytogenetic insights into the pathogenesis, classification, differential diagnosis, and prognosis of renal epithelial neoplasms. Hum. Pathol. 2009, 40(1):10-29.
10. Cheville J.C., et al. Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am. J. Surg. Pathol. 2003, 27(5):612-624.
11. Devlin C., et al. miR-210: more than a silent player in hypoxia. IUBMB Life 2011, 63(2):94-100.
12. Faragalla H., et al. The clinical utility of miR-21 as a diagnostic and prognostic marker for renal cell carcinoma. J.Mol. Diagn. 2012, 14(4):385-392.
13. Farazi T.A., et al. miRNAs in human cancer. J.Pathol. 2011, 223(2):102-115.
14. Ficarra V., et al. Prognostic role of the histologic subtypes of renal cell carcinoma after slide revision. Eur. Urol. 2006, 50(4):786-793. discussion 793-4.
15. Fridman E., et al. Accurate molecular classification of renal tumors using microRNA expression. J.Mol. Diagn. 2010, 12(5):687-696.
16. Fu X., et al. Prognostic role of microRNA-21 in various carcinomas: a systematic review and meta-analysis. Eur. J. Clin. Invest. 2011, 41(11):1245-1253.
17. Gilad S., et al. Classification of the four main types of lung cancer using a microRNA-based diagnostic assay. J.Mol. Diagn 2012, 14(5):510-517.
18. Harada K.I., et al. Expression of epithelial-mesenchymal transition markers in renal cell carcinoma: impact on prognostic outcomes in patients undergoing radical nephrectomy. BJU Int 2012, 110(11 Pt C):E1131-E1137.
19. Huang X., Le Q.T., Giaccia A.J. MiR-210 - micromanager of the hypoxia pathway. Trends Mol. Med. 2010, 16(5):230-237.
20. Korpal M., Kang Y. The emerging role of miR-200 family of microRNAs in epithelial-mesenchymal transition and cancer metastasis. RNA Biol. 2008, 5(3):115-119.
21. Landgraf P., et al. A mammalian microRNA expression atlas based on small RNA library sequencing. Cell 2007, 129(7):1401-1414.
22. Lebanony D., et al. Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from nonsquamous non-small-cell lung carcinoma. J.Clin. Oncol. 2009, 27(12):2030-2037.
23. Lopez-Beltran A., et al. 2004 WHO classification of the renal tumors of the adults. Eur. Urol. 2006, 49(5):798-805.
24. Lopez-Beltran A., et al. Targeted therapies and biological modifiers in urologic tumors: pathobiology and clinical implications. Semin. Diagn. Pathol. 2008, 25(4):232-244.
25. Lopez-Beltran A., et al. 2009 update on the classification of renal epithelial tumors in adults. Int. J. Urol. 2009, 16(5):432-443.
26. Lu J., et al. MicroRNA expression profiles classify human cancers. Nature 2005, 435(7043):834-838.
27. Meiri E., et al. A second-generation microRNA-based assayfor diagnosing tumor tissue origin. Oncologist 2012, 17(6):801-812.
28. Mongroo P.S., Rustgi A.K. The role of the miR-200 family in epithelial-mesenchymal transition. Cancer Biol. Ther. 2010, 10(3):219-222.
29. Najjar Y.G., Rini B.I. Novel agents in renal carcinoma: a reality check. Ther. Adv. Med. Oncol. 2012, 4(4):183-194.
30. Nakada C., et al. Genome-wide microRNA expression profiling in renal cell carcinoma: significant down-regulation of miR-141 and miR-200c. J.Pathol. 2008, 216(4):418-427.
31. Nass D., et al. MiR-92b and miR-9/9 are specifically expressed in brain primary tumors and can be used to differentiate primary from metastatic brain tumors. Brain Pathol. 2009, 19(3):375-383.
32. Rosenfeld N., et al. MicroRNAs accurately identify cancer tissue origin. Nat. Biotechnol. 2008, 26(4):462-469.
33. Shen S.S., et al. Role of immunohistochemistry in diagnosing renal neoplasms: when is it really useful?. Arch. Pathol. Lab. Med. 2012, 136(4):410-417.
34. Steiner G., Sidransky D. Molecular differential diagnosis of renal carcinoma: from microscopes to microsatellites. Am. J. Pathol. 1996, 149(6):1791-1795.
35. Tazi el M., et al. Advanced treatments in non-clear renal cell carcinoma. Urol. J. 2011, 8(1):1-11.
36. Truong L.D., Shen S.S. Immunohistochemical diagnosis of renal neoplasms. Arch. Pathol. Lab. Med. 2011, 135(1):92-109.
37. Vasudev N.S., Selby P.J., Banks R.E. Renal cancer biomarkers: the promise of personalised care. BMC Med. 2012, 10(1):112.
38. Vikram R., et al. Papillary renal cell carcinoma: radiologic-pathologic correlation and spectrum of disease. Radiographics 2009, 29(3):741-754. discussion 755-7.
39. Wang S., et al. The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev. Cell. 2008, 15(2):261-271.
40. White, N.M., G.M. Yousef., 2010. MicroRNAs: exploring a new dimension in the pathogenesis of kidney cancer. BMC Med. 8, p. 65.
41. Youssef Y.M., et al. Accurate molecular classification of kidney cancer subtypes using microRNA signature. Eur. Urol. 2011, 59(5):721-730.
42. Zhou L., et al. Integrated profiling of microRNAs and mRNAs: microRNAs located on Xq27.3 associate with clear cell renal cell carcinoma. PLoS One 2010, 5(12):e15224.